Belluscura - Overview

Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter / more adaptable / have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia / COPD (i.e. asthma/ emphysema /chronic bronchitis) and other respiratory illnesses.

Registrars:

Key Personnel

CEO: Robert “Bob” Rauker
CFO: Simon Neicheril
Non-Executive Director: David Poutney
Executive Director: Robert (Bob) Sylvester Fary
Non-Executive Chairman: Adam Reynolds
Independent Non-Executive Director: Richard John (Ric) Piper, Patrick Strollo

Contact Details

Address: 15 Fetter Lane, London, United Kingdom
Phone: +44 (0) 7814 229686
Fax:
Website: https://www.belluscura.com/
Email:

Listings

ISIN: GB00BD3B8Z11
Sector: Health Care, Health Care
Main Indices: FTSE AIM All-Share